25.06 0.01 (0.04%) | 12-31 19:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 8.14 | 1-year : | 8.86 |
Resists | First : | 6.97 | Second : | 7.59 |
Pivot price | 6.67 | |||
Supports | First : | 5.98 | Second : | 4.97 |
MAs | MA(5) : | 6.73 | MA(20) : | 6.7 |
MA(100) : | 6.56 | MA(250) : | 9.86 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 27.5 | D(3) : | 48.4 |
RSI | RSI(14): 44.2 | |||
52-week | High : | 19.96 | Low : | 4.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CDMO ] has closed above bottom band by 25.0%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 6.6 - 6.64 | 6.64 - 6.67 |
Low: | 6.14 - 6.19 | 6.19 - 6.23 |
Close: | 6.32 - 6.4 | 6.4 - 6.46 |
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Wed, 06 May 2020
Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients ... - GlobeNewswire
Fri, 05 Jan 2018
Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract ... - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 63 (M) |
Shares Float | 58 (M) |
Held by Insiders | 1.1 (%) |
Held by Institutions | 91.9 (%) |
Shares Short | 10,110 (K) |
Shares Short P.Month | 6,590 (K) |
EPS | -0.19 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.9 |
Profit Margin | -8.2 % |
Operating Margin | -44.2 % |
Return on Assets (ttm) | -1.4 % |
Return on Equity (ttm) | -6.3 % |
Qtrly Rev. Growth | -26.9 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 2.22 |
EBITDA (p.s.) | -0.01 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 2 (M) |
Levered Free Cash Flow | -53 (M) |
PE Ratio | -35.5 |
PEG Ratio | -1.8 |
Price to Book value | 2.2 |
Price to Sales | 2.86 |
Price to Cash Flow | 236.31 |
Dividend | 0.66 |
Forward Dividend | 0 |
Dividend Yield | 10.3% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |